BMY

Bristol-Myers Squibb remains a high-quality large-cap biopharma with durable scale in oncology, hematology, and cardiovascular, but its moat is being tested by looming loss-of-exclusivity on key brands. The near-term strategy is to defend cash flows while pivoting to a “growth portfolio” via internal R&D and partnered innovation, including the 2025 BioNTech bispecific collaboration and broader lifecycle/access moves like offering Eliquis through Cost Plus Drugs. Sector-wide pricing pressure and accelerating generic/biosimilar competition make execution and pipeline delivery the core differentiators.

Financially, Q1 2026 results were solid: revenue was $11.5B with GAAP EPS of $1.31 and non-GAAP EPS of $1.58, and management reaffirmed FY2026 guidance for revenue of about $46.0B–$47.5B and non-GAAP EPS of $6.05–$6.35 (both trending to the upper end). Balance sheet leverage is meaningful but manageable: FY2025 cash was about $10.2B versus total debt about $47.2B, with net debt around $34.0B. With a 4%+ dividend yield, the stock’s valuation largely reflects the patent-cliff risk, but higher leverage reduces flexibility if earnings disappoint.

Over the next 12 months, the bull case is a “better-than-feared” erosion curve plus credible late-stage readouts that re-rate the multiple, while continued margin discipline supports EPS delivery. Key catalysts/risks are (1) updated 2026 guidance and commentary on LOE timing/impact, (2) clinical/regulatory outcomes for late-stage assets and partnered programs, and (3) faster-than-expected competitive encroachment on major franchises that pressures cash flow needed for de-leveraging and dividends. For DIY investors, BMY is best framed as an income-plus-valuation recovery setup, not a clean growth story.

Recommendation: HOLD. The yield and reaffirmed FY2026 outlook support downside buffering, but the patent cliff and sizable net debt keep the risk/reward balanced until pipeline catalysts more clearly replace declining legacy revenues.